FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1809-1817 December 20, 2001 Number 25 Next

	Full Text PDF Editorial by Crofford, L. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies.

Methods We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily).

Results Serum thromboxane B₂ levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B₂ formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin.

Conclusions The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.

Source Information

From the EUPenn Group of Investigators at the Center for Experimental Therapeutics (F.C.-L., S.D., B.T., G.A.F.), the Division of Cardiology (M.P.R.), and the General Clinical Research Center (F.C.-L., S.C.K., A.J.C., S.N.V., G.A.F.), University of Pennsylvania School of Medicine, Philadelphia.

Address reprint requests to Dr. FitzGerald at the University of Pennsylvania School of Medicine, 153 Johnson Pavilion, 3620 Hamilton Walk, Philadelphia, PA 19104-6084, or at garret{at}spirit.gcrc.upenn.edu.

Full Text of this Article

Related Letters:

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Burnakis T. G., McQuillan A., Eikelboom J. W., Catella-Lawson F., Reilly M. P., FitzGerald G. A.
Extract | Full Text | PDF  
N Engl J Med 2002; 346:1589-1590, May 16, 2002. Correspondence

This article has been cited by other articles:

• Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D. (2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 0: ken159v1-ken159 [Abstract] [Full Text]  
• Patrignani, P., Capone, M. L, Tacconelli, S. (2008). NSAIDs and cardiovascular disease. Heart 94: 395-397 [Full Text]  
• FitzGerald, G. A. (2008). Summary. Arterioscler. Thromb. Vasc. Bio. 28: s51-s52 [Full Text]  
• Patrono, C., Rocca, B. (2008). Aspirin: Promise and Resistance in the New Millennium. Arterioscler. Thromb. Vasc. Bio. 28: s25-s32 [Abstract] [Full Text]  
• Hinz, B., Cheremina, O., Brune, K. (2008). Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 22: 383-390 [Abstract] [Full Text]  
• Song, W.-L., Wang, M., Ricciotti, E., Fries, S., Yu, Y., Grosser, T., Reilly, M., Lawson, J. A., FitzGerald, G. A. (2008). Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans. J. Biol. Chem. 283: 1179-1188 [Abstract] [Full Text]  
• Schildknecht, S., Daiber, A., Ghisla, S., Cohen, R. A., Bachschmid, M. M. (2008). Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite. FASEB J. 22: 215-224 [Abstract] [Full Text]  
• Gengo, F. M., Rubin, L., Robson, M., Rainka, M., Gengo, M. F., Mager, D. E., Bates, V. (2008). Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. J Clin Pharmacol 48: 117-122 [Abstract] [Full Text]  
• Avalos, I., Chung, C. P., Oeser, A., Milne, G. L., Borntrager, H., Morrow, J. D., Raggi, P., Solus, J., Stein, C. M. (2007). Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus. Lupus 16: 981-986 [Abstract]  
• Ansari, H. R., Nadeem, A., Tilley, S. L., Mustafa, S. J. (2007). Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am. J. Physiol. Heart Circ. Physiol. 293: H3448-H3455 [Abstract] [Full Text]  
• Snoep, J. D., Hovens, M. M. C., Eikenboom, J. C. J., van der Bom, J. G., Huisman, M. V. (2007). Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis. Arch Intern Med 167: 1593-1599 [Abstract] [Full Text]  
• Capone, M. L., Tacconelli, S., Sciulli, M. G., Anzellotti, P., Di Francesco, L., Merciaro, G., Di Gregorio, P., Patrignani, P. (2007). Human Pharmacology of Naproxen Sodium. J. Pharmacol. Exp. Ther. 322: 453-460 [Abstract] [Full Text]  
• Hunt, R. H., Choquette, D., Craig, B. N., De Angelis, C., Habal, F., Fulthorpe, G., Stewart, J. I., Turpie, A. G.G., Davis, P. (2007). Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. cfp 53: 1177-1184 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Farkouh, M E, Greenberg, J D, Jeger, R V, Ramanathan, K, Verheugt, F W A, Chesebro, J H, Kirshner, H, Hochman, J S, Lay, C L, Ruland, S, Mellein, B, Matchaba, P T, Fuster, V, Abramson, S B (2007). Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66: 764-770 [Abstract] [Full Text]  
• Maree, A. O., Fitzgerald, D. J. (2007). Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. Circulation 115: 2196-2207 [Full Text]  
• Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A. (2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 115: 1634-1642 [Full Text]  
• Undas, A., Brummel-Ziedins, K. E., Mann, K. G. (2007). Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109: 2285-2292 [Abstract] [Full Text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full Text]  
• Rahme, E., Nedjar, H. (2007). Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46: 435-438 [Abstract] [Full Text]  
• White, W. B. (2007). Cardiovascular Effects of the Cyclooxygenase Inhibitors. Hypertension 49: 408-418 [Full Text]  
• Rahme, E., Bardou, M., Dasgupta, K., Toubouti, Y., Ghosn, J., Barkun, A. N. (2007). Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 46: 265-272 [Abstract] [Full Text]  
• Zarraga, I. G. E., Schwarz, E. R. (2007). Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know. J Am Coll Cardiol 49: 1-14 [Abstract] [Full Text]  
• Fitzgerald, D. J., Maree, A. (2007). Aspirin and Clopidogrel Resistance. ASH Education Book 2007: 114-120 [Abstract] [Full Text]  
• Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., Kaiser, C., for the BASKET-LATE Investigators, (2006). Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents. J Am Coll Cardiol 48: 2584-2591 [Abstract] [Full Text]  
• Brandt, K. D., Mazzuca, S. A., Buckwalter, K. A. (2006). Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford) 45: 1389-1394 [Abstract] [Full Text]  
• McGettigan, P., Henry, D. (2006). Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 296: 1633-1644 [Abstract] [Full Text]  
• Chaiamnuay, S., Allison, J. J., Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm 63: 1837-1851 [Abstract] [Full Text]  
• Bassand, J.-P. (2006). Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. Eur Heart J Suppl 8: G35-G37 [Abstract] [Full Text]  
• Kurth, T. (2006). Letter by Kurth regarding article, "nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events".. Circulation 114: e495-e495 [Full Text]  
• Chan, A. T., Curhan, G. C., Rimm, E. B., Willett, W. C., Fuchs, C. S., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M. (2006). Response to Letter Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events". Circulation 114: e496-e496 [Full Text]  
• Qi, Z., Cai, H., Morrow, J. D., Breyer, M. D. (2006). Differentiation of Cyclooxygenase 1- and 2-Derived Prostanoids in Mouse Kidney and Aorta. Hypertension 48: 323-328 [Abstract] [Full Text]  
• Bhatt, D. L. (2006). NSAIDS and the risk of myocardial infarction: do they help or harm?. Eur Heart J 27: 1635-1636 [Full Text]  
• Freedman, J. E. (2006). The Aspirin Resistance Controversy: Clinical Entity or Platelet Heterogeneity?. Circulation 113: 2865-2867 [Full Text]  
• Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Kober, L., Madsen, M., Torp-Pedersen, C. (2006). Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation 113: 2906-2913 [Abstract] [Full Text]  
• Hochman, J. S., Shah, N. R. (2006). What Price Pain Relief?. Circulation 113: 2868-2870 [Full Text]  
• Wang, T. H., Bhatt, D. L., Topol, E. J. (2006). Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27: 647-654 [Abstract] [Full Text]  
• Sirvinskas, E., Veikutiene, A., Grybauskas, P., Cimbolaityte, J., Mongirdiene, A., Veikutis, V., Raliene, L. (2006). Influence of aspirin or heparin on platelet function and postoperative blood loss after coronary artery bypass surgery. Perfusion 21: 61-66 [Abstract]  
• Bolten, W W (2006). Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65: 7-13 [Abstract] [Full Text]  
• Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis.. NEJM 353: 2373-2383 [Full Text]  
• Corazzi, T., Leone, M., Maucci, R., Corazzi, L., Gresele, P. (2005). Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016). J. Pharmacol. Exp. Ther. 315: 1331-1337 [Abstract] [Full Text]  
• Hall, F. C., Dalbeth, N. (2005). Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford) 44: 1473-1482 [Abstract] [Full Text]  
• Pijak, M. R., Huzicka, I., Gazdik, F. (2005). The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors. ANN INTERN MED 143: 616-617 [Full Text]  
• Maree, A. O., Curtin, R. J., Dooley, M., Conroy, R. M., Crean, P., Cox, D., Fitzgerald, D. J. (2005). Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. J Am Coll Cardiol 46: 1258-1263 [Abstract] [Full Text]  
• Jermany, J., Branson, J., Schmouder, R., Guillaume, M., Rordorf, C. (2005). Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects. J Clin Pharmacol 45: 1172-1178 [Abstract] [Full Text]  
• Mason, P. J., Jacobs, A. K., Freedman, J. E. (2005). Aspirin Resistance and Atherothrombotic Disease. J Am Coll Cardiol 46: 986-993 [Abstract] [Full Text]  
• Antman, E. M., DeMets, D., Loscalzo, J. (2005). Cyclooxygenase Inhibition and Cardiovascular Risk. Circulation 112: 759-770 [Full Text]  
• Flume, P. A., Yankaskas, J. R., Ebeling, M., Hulsey, T., Clark, L. L. (2005). Massive Hemoptysis in Cystic Fibrosis. Chest 128: 729-738 [Abstract] [Full Text]  
• Saseen, J. J. (2005). ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events. Am J Health Syst Pharm 62: 1398-1405 [Full Text]  
• Konstantinopoulos, P. A., Lehmann, D. F. (2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. J Clin Pharmacol 45: 742-750 [Abstract] [Full Text]  
• Corman, S. L, Fedutes, B. A, Ansani, N. T (2005). Impact of Nonsteroidal Antiinflammatory Drugs on the Cardioprotective Effects of Aspirin. The Annals of Pharmacotherapy 39: 1073-1079 [Abstract] [Full Text]  
• Bates, E. R., Lau, W. C. (2005). Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease. Circulation 111: e267-e271 [Full Text]  
• Lehmann, D. F. (2005). Arthritis Medications and Cardiovascular Events. JAMA 293: 1976-1976 [Full Text]  
• Capone, M. L., Sciulli, M. G., Tacconelli, S., Grana, M., Ricciotti, E., Renda, G., Di Gregorio, P., Merciaro, G., Patrignani, P. (2005). Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45: 1295-1301 [Abstract] [Full Text]  
• Steinhubl, S. R. (2005). The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain. J Am Coll Cardiol 45: 1302-1303 [Full Text]  
• Bennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., Taubert, K. A. (2005). The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association. Circulation 111: 1713-1716 [Full Text]  
• Ridker, P. M, Cook, N. R., Lee, I-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., Buring, J. E. (2005). A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. NEJM 352: 1293-1304 [Abstract] [Full Text]  
• Dickman, A., Ellershaw, J. (2005). A reply to Dr Davis and other correspondents. Palliat Med 19: 166-167  
• Sanderson, S., Emery, J., Baglin, T., Kinmonth, A.-L. (2005). Narrative Review: Aspirin Resistance and Its Clinical Implications. ANN INTERN MED 142: 370-380 [Abstract] [Full Text]  
• Finckh, A., Aronson, M. D. (2005). Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now. ANN INTERN MED 142: 212-214 [Full Text]  
• Jin, Y.-R., Cho, M.-R., Ryu, C.-K., Chung, J.-H., Yuk, D.-Y., Hong, J.-T., Lee, K.-S., Lee, J.-J., Lee, M.-Y., Lim, Y., Yun, Y.-P. (2005). Antiplatelet Activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an Antithrombotic Agent, Is Mediated by Thromboxane (TX) A2 Receptor Blockade with TXA2 Synthase Inhibition and Suppression of Cytosolic Ca2+ Mobilization. J. Pharmacol. Exp. Ther. 312: 214-219 [Abstract] [Full Text]  
• Hassan, A. A., Kroll, M. H. (2005). Acquired Disorders of Platelet Function. ASH Education Book 2005: 403-408 [Abstract] [Full Text]  
• Fries, S., Grosser, T. (2005). The Cardiovascular Pharmacology of COX-2 Inhibition. ASH Education Book 2005: 445-451 [Abstract] [Full Text]  
• Kim, P. S., Reicin, A. S., Villalba, L., Witter, J., Wolfe, M. M., Topol, E. J. (2004). Rofecoxib, Merck, and the FDA. NEJM 351: 2875-2878 [Full Text]  
• Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y., Burns, J. C., Shulman, S. T., Bolger, A. F., Ferrieri, P., Baltimore, R. S., Wilson, W. R., Baddour, L. M., Levison, M. E., Pallasch, T. J., Falace, D. A., Taubert, K. A. (2004). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114: 1708-1733 [Abstract] [Full Text]  
• Cattaneo, M. (2004). Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance. Arterioscler. Thromb. Vasc. Bio. 24: 1980-1987 [Abstract] [Full Text]  
• Kojda, G. (2004). Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?. Cardiovasc Res 64: 192-194 [Full Text]  
• Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y., Burns, J. C., Shulman, S. T., Bolger, A. F., Ferrieri, P., Baltimore, R. S., Wilson, W. R., Baddour, L. M., Levison, M. E., Pallasch, T. J., Falace, D. A., Taubert, K. A. (2004). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110: 2747-2771 [Abstract] [Full Text]  
• Schulman, S. P. (2004). Antiplatelet Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes. JAMA 292: 1875-1882 [Abstract] [Full Text]  
• Kulik, A., Ruel, M., Bourke, M. E., Sawyer, L., Penning, J., Nathan, H. J., Mesana, T. G., Bedard, P. (2004). Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial. Eur. J. Cardiothorac. Surg. 26: 694-700 [Abstract] [Full Text]  
• Hennekens, C. H., Schror, K., Weisman, S., FitzGerald, G. A. (2004). Terms and Conditions: Semantic Complexity and Aspirin Resistance. Circulation 110: 1706-1708 [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• van Ryn, J., Kink-Eiband, M., Kuritsch, I., Feifel, U., Hanft, G., Wallenstein, G., Trummlitz, G., Pairet, M. (2004). Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers. J Clin Pharmacol 44: 777-784 [Abstract] [Full Text]  
• Garcia Rodriguez, L. A., Varas-Lorenzo, C., Maguire, A., Gonzalez-Perez, A. (2004). Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation 109: 3000-3006 [Abstract] [Full Text]  
• Cox, E. R., Frisse, M., Behm, A., Fairman, K. A. (2004). Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users. Arch Intern Med 164: 1243-1246 [Full Text]  
• Dickman, A., Ellershaw, J. (2004). For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?. Palliat Med 18: 275-286 [Abstract]  
• McCabe, D. J.H., Harrison, P., Machin, S. J., Watt, H., Brown, M. M., Alberts, M. J. (2004). Measurement of the Antiplatelet Effects of Aspirin in Cerebrovascular Disease * Response. Stroke 35: e146-e147 [Full Text]  
• Goodson, N. J., Silman, A. J., Pattison, D. J., Lunt, M., Bunn, D., Luben, R., Day, N., Khaw, K.-T., Symmons, D. P. M. (2004). Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 43: 731-736 [Abstract] [Full Text]  
• WARNER, T. D., MITCHELL, J. A. (2004). Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18: 790-804 [Abstract] [Full Text]  
• Patel, T. N., Goldberg, K. C. (2004). Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction. Arch Intern Med 164: 852-856 [Abstract] [Full Text]  
• Blaicher, A. M., Landsteiner, H. T., Al-Falaki, O., Zwerina, J., Volf, I., Gruber, D., Zimpfer, M., Hoerauf, K. (2004). Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression. Anesth. Analg. 98: 1082-1085 [Abstract] [Full Text]  
• Kimmel, S. E., Berlin, J. A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J., Strom, B. L. (2004). The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 43: 985-990 [Abstract] [Full Text]  
• Curtis, J. P., Krumholz, H. M. (2004). The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs: Is it time to believe the hype?. J Am Coll Cardiol 43: 991-993 [Full Text]  
• Bhatt, D. L. (2004). Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 43: 1127-1129 [Full Text]  
• Eliasziw, M. T., Hill, M. D., Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., Gaziano, J. M. (2004). Throw Away the Aspirin and Take Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Myocardial Infarction * Response. Circulation 109: e65-66 [Full Text]  
• Howard, P. A., Delafontaine, P. (2004). Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 43: 519-525 [Abstract] [Full Text]  
• Patrono, C., Bachmann, F., Baigent, C., Bode, C., De Caterina, R., Charbonnier, B., Fitzgerald, D., Hirsh, J., Husted, S., Kvasnicka, J., Montalescot, G., Garcia Rodriguez, L. A., Verheugt, F., Vermylen, J., Wallentin, L., ESC Committee for Practice Guidelines, , Priori, S. G, Alonso Garcia, M. A., Blanc, J.-J., Budaj, A., Cowie, M., Dean, V., Deckers, J., Fernandez Burgos, E., Lekakis, J., Lindahl, B., Mazzotta, G., Morais, J., Oto, A., Smiseth, O. A, Document Reviewers, , Morais, J., Deckers, J., Ferreira, R., Mazzotta, G., Steg, P.-G., Teixeira, F., Wilcox, R. (2004). Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 25: 166-181 [Full Text]  
• Alberts, M. J., Bergman, D. L., Molner, E., Jovanovic, B. D., Ushiwata, I., Teruya, J. (2004). Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease. Stroke 35: 175-178 [Abstract] [Full Text]  
• Kimmel, S. E, Strom, B. L (2003). Giving aspirin and ibuprofen after myocardial infarction. BMJ 327: 1298-1299 [Full Text]  
• Silverman, D. G., Halaszynski, T., Sinatra, R., Luther, M., Rinder, C. S. (2003). Rofecoxib does not compromise platelet aggregation during anesthesia and surgery: [Le rofecoxib n'altere pas l'agregation plaquettaire pendant l'anesthesie et la chirurgie]. Canadian J. Anesthesia 50: 1004-1008 [Abstract] [Full Text]  
• Title, L. M., Giddens, K., McInerney, M. M., McQueen, M. J., Nassar, B. A. (2003). Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 42: 1747-1753 [Abstract] [Full Text]  
• Bates, E. R, Mukherjee, D., Lau, W. C (2003). Drug-drug interactions involving antiplatelet agents. Eur Heart J 24: 1707-1709 [Full Text]  
• Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., Gaziano, J. M. (2003). Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs. Circulation 108: 1191-1195 [Abstract] [Full Text]  
• Burke, J., Kraft, W. K., Greenberg, H. E., Gleave, M., Pitari, G. M., VanBuren, S., Wagner, J. A., Waldman, S. A. (2003). Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. J Clin Pharmacol 43: 983-989 [Abstract] [Full Text]  
• Schafer, A. I. (2003). Genetic and Acquired Determinants of Individual Variability of Response to Antiplatelet Drugs. Circulation 108: 910-911 [Full Text]